Lipoxin A4 protects against lipopolysaccharide-induced sepsis by promoting innate response activator B cells generation

International Immunopharmacology

Volumn 39, Issue , 2016, Pages 229-235

  Cheng, Qiong ^a,b   Wang, Zheng ^a   Ma, Ruihua ^a   Chen, Yongtao ^a   Yan, Yan ^a   Miao, Shuo ^a   Jiao, Jingyu ^a   Cheng, Xue ^a   Kong, Lingfei ^b   Ye, Duyun ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

B cells; Granulocyte macrophage colony stimulating factor; Lipoxin A4; Sepsis; Signal transducer and activator of transcription 5

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOXIN A; STAT5 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; LIPOPOLYSACCHARIDE; LIPOXIN;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; B LYMPHOCYTE ACTIVATION; CELL DIFFERENTIATION; CELL EXPANSION; CONTROLLED STUDY; FEMALE; INNATE IMMUNITY; INNATE RESPONSE ACTIVATOR B CELL; LIPOPOLYSACCHARIDE-INDUCED SEPSIS; LYMPHOCYTE MIGRATION; MOUSE; NONHUMAN; PERITONEAL FLUID LEVEL; PERITONEUM LAVAGE; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SPLEEN CELL; SPLENECTOMY; SPLENIC TISSUE; ANIMAL; B LYMPHOCYTE; BAGG ALBINO MOUSE; CELL CULTURE; CELL MOTION; CELL PROLIFERATION; CHEMICALLY INDUCED; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; SEPSIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; B-LYMPHOCYTES; CELL DIFFERENTIATION; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; FEMALE; IMMUNITY, INNATE; LIPOPOLYSACCHARIDES; LIPOXINS; MICE; MICE, INBRED BALB C; SEPSIS; STAT5 TRANSCRIPTION FACTOR;

EID: 84979912980     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2016.07.026     Document Type: Article

References (35)

1. [1] Bosmann, M., Ward, P.A., The inflammatory response in sepsis. Trends Immunol. 34 (2013), 129–136.
2. [2] Rittirsch, D., Flierl, M.A., Ward, P.A., Harmful molecular mechanisms in sepsis. Nat. Rev. Immunol. 8 (2008), 776–787.
3. [3] Boomer, J.S., K. To, Chang, K.C., Takasu, O., Osborne, D.F., Walton, A.H., Bricker, T.L., Jarman, S.D., Kreisel, D., Krupnick, A.S., Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 306 (2011), 2594–2605.
4. [4] Shen, P., Fillatreau, S., Antibody-independent functions of B cells: a focus on cytokines. Nat. Rev. Immunol., 2015.
5. [5] Candando, K.M., Lykken, J.M., Tedder, T.F., B10 cell regulation of health and disease. Immunol. Rev. 259 (2014), 259–272.
6. [6] Mauri, C., Bosma, A., Immune regulatory function of B cells. Annu. Rev. Immunol. 30 (2012), 221–241.
7. [7] León, B., Ballesteros-Tato, A., Browning, J.L., Dunn, R., Randall, T.D., Lund, F.E., Regulation of TH2 development by CXCR5 + dendritic cells and lymphotoxin-expressing B cells. Nat. Immunol. 13 (2012), 681–690.
8. [8] Menard, L.C., Minns, L.A., Darche, S., Mielcarz, D.W., Foureau, D.M., Roos, D., Dzierszinski, F., Kasper, L.H., Buzoni-Gatel, D., B cells amplify IFN-γ production by T cells via a TNF-α-mediated mechanism. J. Immunol. 179 (2007), 4857–4866.
9. [9] Wojciechowski, W., Harris, D.P., Sprague, F., Mousseau, B., Makris, M., Kusser, K., Honjo, T., Mohrs, K., Mohrs, M., Randall, T., Cytokine-producing effector B cells regulate type 2 immunity to H. polygyrus. Immunity 30 (2009), 421–433.
10. [10] Karnowski, A., Chevrier, S., Belz, G.T., Mount, A., Emslie, D., D'Costa, K., Tarlinton, D.M., Kallies, A., Corcoran, L.M., B and T cells collaborate in antiviral responses via IL-6, IL-21, and transcriptional activator and coactivator, Oct2 and OBF-1. J. Exp. Med. 209 (2012), 2049–2064.
11. [11] Bermejo, D.A., Jackson, S.W., Gorosito-Serran, M., Acosta-Rodriguez, E.V., Amezcua-Vesely, M.C., Sather, B.D., Singh, A.K., Khim, S., Mucci, J., Liggitt, D., Trypanosoma cruzi trans-sialidase initiates a program independent of the transcription factors ROR [gamma] t and Ahr that leads to IL-17 production by activated B cells. Nat. Immunol. 14 (2013), 514–522.
12. [12] Bao, Y., Liu, X., Han, C., Xu, S., Xie, B., Zhang, Q., Gu, Y., Hou, J., Qian, L., Qian, C., Identification of IFN-γ-producing innate B cells. Cell Res. 24 (2014), 161–176.
13. [13] Fillatreau, S., Sweenie, C.H., McGeachy, M.J., Gray, D., Anderton, S.M., B cells regulate autoimmunity by provision of IL-10. Nat. Immunol. 3 (2002), 944–950.
14. [14] Shen, P., Roch, T., Lampropoulou, V., O'Connor, R.A., Stervbo, U., Hilgenberg, E., Ries, S., Jaimes, Y., Daridon, C., Li, R., IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature 507 (2014), 366–370.
15. [15] Wang, R.-X., Yu, C.-R., Dambuza, I.M., Mahdi, R.M., Dolinska, M.B., Sergeev, Y.V., Wingfield, P.T., Kim, S.-H., Egwuagu, C.E., Interleukin-35 induces regulatory B cells that suppress autoimmune disease. Nat. Med. 20 (2014), 633–641.
16. [16] Rauch, P.J., Chudnovskiy, A., Robbins, C.S., Weber, G.F., Etzrodt, M., Hilgendorf, I., Tiglao, E., Figueiredo, J.-L., Iwamoto, Y., Theurl, I., Innate response activator B cells protect against microbial sepsis. Science 335 (2012), 597–601.
17. [17] Weber, G.F., Chousterman, B.G., Hilgendorf, I., Robbins, C.S., Theurl, I., Gerhardt, L.M., Iwamoto, Y., Quach, T.D., Ali, M., Chen, J.W., Pleural innate response activator B cells protect against pneumonia via a GM-CSF-IgM axis. J. Exp. Med. 211 (2014), 1243–1256.
18. [18] Serhan, C.N., Chiang, N., Van Dyke, T.E., Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat. Rev. Immunol. 8 (2008), 349–361.
19. [19] Machado, F.S., Aliberti, J., Role of lipoxin in the modulation of immune response during infection. Int. Immunopharmacol. 8 (2008), 1316–1319.
20. [20] Walker, J., Dichter, E., Lacorte, G., Kerner, D., Spur, B., Rodriguez, A., Yin, K., Lipoxin a4 increases survival by decreasing systemic inflammation and bacterial load in sepsis. Shock 36 (2011), 410–416.
21. [21] Tsai, W.-H., Shih, C.-H., Yu, Y.-B., Hsu, H.-C., Plasma levels in sepsis patients of annexin A1, lipoxin A4, macrophage inflammatory protein-3a, and neutrophil gelatinase-associated lipocalin. J. Chin. Med. Assoc. 76 (2013), 486–490.
22. [22] Ramon, S., Bancos, S., Serhan, C.N., Phipps, R.P., Lipoxin A4 modulates adaptive immunity by decreasing memory B-cell responses via an ALX/FPR2-dependent mechanism. Eur. J. Immunol. 44 (2014), 357–369.
23. [23] Spurr, L., Nadkarni, S., Pederzoli-Ribeil, M., Goulding, N.J., Perretti, M., D'Acquisto, F., Comparative analysis of Annexin A1-formyl peptide receptor 2/ALX expression in human leukocyte subsets. Int. Immunopharmacol. 11 (2011), 55–66.
24. [24] Wang, Z., Cheng, Q., Tang, K., Sun, Y., Zhang, K., Zhang, Y., Luo, S., Zhang, H., Ye, D., Huang, B., Lipid mediator lipoxin A4 inhibits tumor growth by targeting IL-10-producing regulatory B (Breg) cells. Cancer Lett., 2015.
25. [25] Metcalf, D., Nicola, N.A., Mifsud, S., Di Rago, L., Receptor clearance obscures the magnitude of granulocyte-macrophage colony-stimulating factor responses in mice to endotoxin or local infections. Blood 93 (1999), 1579–1585.
26. [26] Lu, T.T., Cyster, J.G., Integrin-mediated long-term B cell retention in the splenic marginal zone. Science 297 (2002), 409–412.
27. [27] Sheng, W., Yang, F., Zhou, Y., Yang, H., Low, P.Y., Kemeny, D.M., Tan, P., Moh, A., Kaplan, M.H., Zhang, Y., STAT5 programs a distinct subset of GM-CSF-producing T helper cells that is essential for autoimmune neuroinflammation. Cell Res., 2014.
28. [28] Li, R., Rezk, A., Miyazaki, Y., Hilgenberg, E., Touil, H., Shen, P., Moore, C.S., Michel, L., Althekair, F., Rajasekharan, S., Gommerman, J.L., Prat, A., Fillatreau, S., Bar-Or, A., Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy. Sci. Transl. Med., 7, 2015, 310ra166.
29. [29] Liu, H., Liu, Z., Zhao, S., Sun, C., Yang, M., Effect of BML-111 on the intestinal mucosal barrier in sepsis and its mechanism of action. Mol. Med. Rep. 12 (2015), 3101–3106.
30. [30] Wu, B., Walker, J., Spur, B., Rodriguez, A., Yin, K., Effects of Lipoxin A 4 on antimicrobial actions of neutrophils in sepsis, Prostaglandins. Leukot. Essent. Fat. Acids (PLEFA) 94 (2015), 55–64.
31. [31] Muenzer, J.T., Davis, C.G., Chang, K., Schmidt, R.E., Dunne, W.M., Coopersmith, C.M., Hotchkiss, R.S., Characterization and modulation of the immunosuppressive phase of sepsis. Infect. Immun. 78 (2010), 1582–1592.
32. [32] Shi, Y., Liu, C.H., Roberts, A.I., Das, J., Xu, G., Ren, G., Zhang, Y., Zhang, L., Yuan, Z.R., Tan, H.S.W., Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don't know. Cell Res. 16 (2006), 126–133.
33. [33] Wu, B., Walker, J.A., Temmermand, D., Mian, K., Spur, B., Rodriguez, A., Stein, T.P., Banerjee, P., Yin, K., Lipoxin A(4) promotes more complete inflammation resolution in sepsis compared to stable lipoxin A(4) analog. Prostaglandins Leukot. Essent. Fat. Acids 89 (2013), 47–53.
34. [34] Yanaba, K., Yoshizaki, A., Asano, Y., Kadono, T., Tedder, T.F., Sato, S., IL-10–producing regulatory B10 cells inhibit intestinal injury in a mouse model. Am. J. Pathol. 178 (2011), 735–743.
35. [35] Wan, C.-K., Oh, J., Li, P., West, E.E., Wong, E.A., Andraski, A.B., Spolski, R., Yu, Z.-X., He, J., Kelsall, B.L., The cytokines IL-21 and GM-CSF have opposing regulatory roles in the apoptosis of conventional dendritic cells. Immunity 38 (2013), 514–527.